Alfacell's Research With ONCONASE Expands to Pacific-Rim; Data Presented At the Japan Cytometry Society Meeting, August 2000.Business Editors BLOOMFIELD, N.J.--(BUSINESS WIRE)--Aug. 15, 2000 Alfacell Corporation (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ACEL ACEL Australian Council for Educational Leaders (Australia) ACEL Aerospace Crew Equipment Laboratory ACEL Alternating Current Electro-Luminescent ). An Alfacell collaborator, Tomoyuki Murakami, M.D., Ph.D., Chief Researcher of the Department of Clinical Research of the National Sanyo Hospital, Ube, Yamaguchi, Japan, presented pre-clinical research results with ONCONASE(R) at the Japan Cytometry Society Meeting. The meeting was held in Tokyo from August 4th to 6th, 2000. These results also have been accepted for publication in the journal Cell Proliferation. A significant increase (200%-400%) in tumor cell death (apoptosis) was observed when either all-trans-retinoic acid or phenylbutyrate was added to leukemia and prostate cell lines treated with ONCONASE, respectively. These agents are currently used in the treatment of some forms of adult leukemia and prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . Such findings suggest that the addition of ONCONASE to regimens for patients with certain forms of leukemia or prostate cancer may improve the therapeutic effectiveness of these regimens. Dr. Stan Mikulski, Alfacell's Medical Director and Exec. VP, stated "These data corroborate To support or enhance the believability of a fact or assertion by the presentation of additional information that confirms the truthfulness of the item. The testimony of a witness is corroborated if subsequent evidence, such as a coroner's report or the testimony of other our initial published reports and findings showing the synergistic impact of ONCONASE in producing significant anti-tumor activity both in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and in vivo. We are excited to continue to expand upon the possible clinical opportunities of ONCONASE". Alfacell is continuing its collaborative effort with Japanese scientists, and the research program has been expanded to include non-small cell lung and head and neck cancers. ONCONASE (ranpirnase) is a novel ribonuclease Ribonuclease A group of enzymes, widely distributed in nature, which catalyze hydrolysis of the internucleotide phosphodiester bonds in ribonucleic acid (RNA). that is unique among the superfamily superfamily /su·per·fam·i·ly/ (soo´per-fam?i-le) 1. a taxonomic category between an order and a family. 2. of pancreatic ribonuclease. To date, over 700 patients have been treated with ONCONASE and the treatment was associated with only modest side effects. In addition, in conjunction with the studies performed by the National Cancer Institute, Developmental Therapeutics Program, ONCONASE has shown significant anti-cancer activity in several animal tumor models. ALFACELL Corporation is a leader in the development of ribonucleases (RNases) for therapeutic applications. ONCONASE, an anti-tumor agent is currently being investigated in Phase III clinical trials in patients with malignant mesothelioma. Alfacell is located in Bloomfield, New Jersey, and the Company's common stock is traded in the over-the-counter market under the symbol "ACEL". |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion